Syngene International Limited has released an investor presentation on December 17, 2025, detailing its capabilities and the market landscape for clinical trials. This presentation, shared with investors and analysts, reiterates that no new information beyond publicly available data will be disclosed. The company highlights the growing global CRDMO market, projected to reach $370 billion by 2029, with the Clinical CRO segment being a significant and fast-growing part. The presentation emphasizes the increasing R&D pipeline, patient diversity needs, the rise of virtual biotech companies, cost advantages in outsourcing to APAC, and the overall acceleration of R&D outsourcing as key growth drivers for the clinical CRO market. India is identified as a particularly attractive market, expected to grow at a 16% CAGR from 2024-2028, driven by a large patient pool, skilled workforce, and a supportive regulatory environment. Syngene's Translational and Clinical Research (T&CR) business is presented as an integral part of its Research Services. The company showcases its integrated continuum from discovery to commercialization, a global clinical network, and a diversified platform supported by investments in new modalities and digital/AI. Key strengths include its Human Pharmacology Unit, Clinical Trial Services, Bioanalytical services, and Central Lab Services. The T&CR business operates on a 2-way and 3-way model, with contracts typically spanning 15 to 24 months or longer for global trials. The strategic focus is on supporting complex trials, strengthening existing functions, and forward integration into subsequent trial phases. The presentation also included a webinar on the Clinical Trials Market, led by Dr. Mrinal Kammili, Head of Translational & Clinical Research. The webinar provided an overview of the Clinical Trials Industry and Syngene's T&CR business, with a Q&A session addressing industry and business model aspects. Syngene announced a deal in Q2 FY26 for a global phase III clinical trial with a U.S.-based biotech company, which will recruit patients in India and the U.S.